|1.||Steer, Clifford J: 12 articles (05/2014 - 01/2002)|
|2.||Rodrigues, Cecília M P: 6 articles (01/2015 - 11/2004)|
|3.||Low, Walter C: 6 articles (05/2014 - 01/2002)|
|4.||Rodrigues, Cecilia M P: 6 articles (01/2007 - 01/2002)|
|5.||Solá, Susana: 4 articles (01/2014 - 04/2002)|
|6.||Castro, Rui E: 4 articles (01/2007 - 05/2003)|
|7.||Pardue, Machelle T: 3 articles (01/2016 - 01/2006)|
|8.||Boatright, Jeffrey H: 3 articles (01/2016 - 01/2006)|
|9.||Park, Sang Gyu: 3 articles (03/2015 - 11/2011)|
|10.||Amaral, Joana D: 3 articles (01/2015 - 09/2009)|
|1.||Wounds and Injuries (Trauma)
06/01/2008 - "Rats in group 3 were treated with TUDCA (200 mg/kg intraperitoneal) 1 min after trauma. "
04/01/2002 - "Thus, TUDCA, a clinically safe molecule, may be useful in the treatment of stroke and possibly other apoptosis-associated acute and chronic injuries to the brain."
06/01/2008 - "To our knowledge, this is the first study in the English language to evaluate the therapeutic efficacy of TUDCA in an experimental model of SCI. Thirty rats were randomized into three groups (sham-operated, trauma only, and trauma plus TUDCA treatment) of 10 each. "
04/01/2002 - "Tauroursodeoxycholic acid administered 1 hour after ischemia resulted in significantly increased bile acid levels in the brain, improved neurologic function, and an approximately 50% reduction in infarct size 2 and 7 days after reperfusion. "
03/01/2015 - "In GFP(+) bone marrow-transplanted hind limb ischemia, TUDCA induced recruitment of GFP(+) /c-kit(+) progenitors to the ischemic area, resulting in an increased blood perfusion ratio. "
03/01/2015 - "In the mouse hind limb ischemia model, TUDCA promoted blood perfusion by enhancing angiogenesis through recruitment of Flk-1(+) /CD34(+) and Sca-1(+) /c-kit(+) progenitors into damaged tissue. "
10/01/1998 - "At 3 hr after 1 hr of ischemia and reperfusion in 70% rat liver, high-dose TUDCA reduced hepatic reperfused injury according to biochemical and histological findings and significantly increased bile flow after reperfusion. "
11/01/1991 - "The results show that stimulation of bile flow either by TCA, UDCA or TUDCA does not reduce ischemia-reperfusion liver injury. "
|3.||Liver Cirrhosis (Hepatic Cirrhosis)
04/01/2013 - "We designed a double-blind randomized trial to evaluate the potential therapeutic efficacy of TUDCA in liver cirrhosis, using UDCA as parallel control. "
04/01/2013 - "It is suggested that TUDCA therapy is safe and appears to be more effective than UDCA in the treatment of liver cirrhosis, particularly in the improvement of the biochemical expression. "
04/01/2013 - "The enrolled 23 patients with liver cirrhosis were randomly divided into TUDCA group (n=12) and UDCA group (n=11), and given TUDCA and UDCA respectively at the daily dose of 750 mg, in a randomly assigned sequence for a 6-month period. "
04/01/2013 - "Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: a double-blind randomized controlled trial."
01/01/2012 - "To look for substitute for bear bile, the aim of this study is to compare the anti-fibrotic effects of Coptidis Rhizoma and its major component berberine with the actions of bear bile and its major compound tauroursodeoxycholic acid on experimental liver fibrosis in rats. "
|4.||Neurodegenerative Diseases (Neurodegenerative Disease)
08/01/2015 - "As demonstrated for other neurodegenerative diseases, we now show that TUDCA and UDCA may have a therapeutic role in prion diseases, with effects on both prion conversion and neuroprotection. "
01/01/2014 - "These results report novel TUDCA anti-inflammatory actions, with potential therapeutic implications for neurodegenerative diseases, including retinitis pigmentosa."
11/01/2004 - "These data suggest that TUDCA may be beneficial in treating neurodegenerative disorders in which increased glutamate levels contribute to the pathogenesis of the disease."
01/01/2014 - "In addition, the endogenous bile acid, tauroursodeoxycholic acid (TUDCA) was shown to be neuroprotective in several animal models of neurodegenerative disorders by acting as an anti-apoptotic and anti-oxidant molecule at the mitochondrial level. "
10/01/2012 - "Tauroursodeoxycholic acid (TUDCA) acts as a mitochondrial stabilizer and anti-apoptotic agent in several models of neurodegenerative diseases. "
01/01/2014 - "Microglia activation in a model of retinal degeneration and TUDCA neuroprotective effects."
07/01/2011 - "The neuroprotective effects of TUDCA make this compound potentially useful for delaying retinal degeneration in RP."
07/01/2011 - "Tauroursodeoxycholic acid prevents retinal degeneration in transgenic P23H rats."
01/01/2006 - "Systemic injection of TUDCA, a primary constituent of bear bile, profoundly suppressed apoptosis and preserved function and morphology of photoreceptor cells in two disparate mouse models of retinal degeneration. "
01/01/2006 - "By every measure, TUDCA greatly slowed retinal degeneration in LIRD and rd10 mice. "
|3.||salicylhydroxamic acid (SHAM)
|5.||Ethanol (Ethyl Alcohol)
|6.||Blood Glucose (Blood Sugar)
|7.||Alcohol Dehydrogenase (Alcohol Dehydrogenase (NAD+))
|8.||Activating Transcription Factor 6
|9.||Glutamic Acid (Glutamate)
|1.||Transplantation (Transplant Recipients)